Merck's Keytruda Hits Key Endpoint in Metastatic Triple-Negative Breast Cancer
July 27 2021 - 7:51AM
Dow Jones News
By Colin Kellaher
Merck & Co. Tuesday said a pivotal Phase 3 study of its
cancer drug Keytruda in combination with chemotherapy met a primary
endpoint of overall survival in metastatic triple-negative breast
cancer.
The Kenilworth, N.J., drugmaker said the combination showed a
statistically significant and clinically meaningful improvement in
overall survival compared with chemotherapy alone in patients whose
tumors expressed PD-L1 with a combined positive score of at least
10.
Merck said Keytruda is the first anti-PD-1 therapy in
combination with chemotherapy to show statistically significant
overall survival for that patient population. The company
previously reported that the combination had shown significantly
improved progression-free survival.
Merck is studying Keytruda, a cancer drug that harnesses a
patient's immune system to fight tumors, across multiple settings
and stages of triple-negative breast cancer, the subtype with the
worst survival prognosis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 27, 2021 07:42 ET (11:42 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024
